secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-08-15T23:59:59+00:00
Accession:  0001615219-25-000101
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharmaceuticals effects 1-for-15 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split effective 5:00 p.m. ET on August 15, 2025; trading on split-adjusted basis from August 18, 2025.
- Shares outstanding reduced from ~7.6M to ~509,000; no fractional shares, cash in lieu paid.
- New CUSIP number 79400X503; authorized shares and par value unchanged.
- Split approved by stockholders at July 8, 2025 special meeting; ratio set by Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000101/0001615219-25-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000101/flks-20250815.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer